Femasys doubles enrolling sites to 12 in FemBloc FINALE pivotal trial
FEMY•Femasys doubled the number of actively enrolling U.S. sites to 12 for its FemBloc FINALE pivotal trial. The company said the expansion is intended to support completion of the U.S. study and an FDA filing; no trial results were presented.
1. Enrollment sites expand
Femasys doubled actively enrolling U.S. sites to 12 for its FemBloc FINALE pivotal trial of non-surgical permanent birth control. The expansion is intended to support completion of the U.S. study and an FDA filing, and no trial results were presented.
2. Product and Europe
FemBloc is positioned as an office-based alternative to surgical sterilization that aims to avoid anesthesia, incisions and recovery time. The product has been cleared in Europe, where post-market real-world evidence collection is intended to complement the U.S. pivotal dataset.
